Russian Heart Failure Journal 2014year Acute decompensated heart failure. Consensus of Russian experts, 2014


To access this material please log in or register

Register Authorize
2014/№5

Acute decompensated heart failure. Consensus of Russian experts, 2014

Mareev V. Yu.1, Arutyunov G. P.2, Astashkin E. I.3, Vertkin A. L.4, Glezer M. G.3, Lopatin Yu. M.5, Matskeplishvili S. T.6, Mareev Yu. V.7, Sitnikova M. Yu.8, Fomin I. V.9, Khirmanov V. N.10
1 – Lomonosov Moscow State University, GSP-1, Leninskie Gory 1, Moscow, 119991
2 – “Pirogov Russian National Research Medical University” MPH RF, Ostrovitianov 1, Moscow, Russia, 117997
3 – “I. M. Sechenov First Moscow State Medical University” MPH RF, Trubetskaya 8-2, Moscow, 119991
4 – “A.I. Evdokimov Moscow State University of Medicine and Dentistry” MPH RF, Delegatskaya 20-1, Moscow, 127473
5 – “Volgograd State Medical University” MPH RF, Fallen Fighters Square 1, Volgograd, 400131
6 – “Bakoulev Scientific Center for Cardiovascular Surgery” RAMS, Leninsky Prospekt 8-7, Moscow, 117931
7 – “Russian Cardiology Research and Production Complex” MPH RF, 3-Cherepkovskaya 15a, Moscow, 121552
8 – “Federal Almazov Medical Research Centre” MPH RF, Akkuratova 2, St. Petersburg, 197341
9 – “Nizhny Novgorod State Medical Academy” MPH RF, Minin and Pozharsky plaza 10 / 1, Nizhny Novgorod, 603005
10
Federal State Institute of Public Health “The Nikiforov Russian Center of Emergency and Radiation Medicine”
EMERCOM of Russia, Acad. Lebedev 4/2, St. Petersburg, 194044

Keywords: circulatory decompensation, acute heart failure


DOI: 10.18087/rhfj.2014.5.2024

  1. Фомин И. В., Беленков Ю. Н., Мареев В. Ю. и др. Распро­­страненность хронической сердечной недостаточности в Евро­­пейской части Российской Федерации – данные ЭПОХА–ХСН. Журнал Сердечная Недостаточность. 2006;7 (3):112–115.
  2. Беленков Ю. Н. Мареев В. Ю. Лечение сердечной недостаточности в 21 веке: достижение, вопросы и уроки доказательной медицины. Кардиология 2008;48 (2):6–16.
  3. Maggioni AP, Dahlstrom U, Filippatos G et al. EURObservational Research Programme: regional differences and 1‑year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail. 2013;15 (7):808–17.
  4. Setoguchi S, Stevenson LW, Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. Am Heart J. 2007 Aug;154 (2):260–6.
  5. Cowie MR, Anker SD, Cleland J et al. Improving care for patients with acute heart failure: before, during and after hospitalization. Oxford, UK: Oxford PharmaGenesis™; 2014. Available at: http://www.oxfordhealthpolicyforum.org / reports / acute-heart-failure / improving-care-for-patients-with-acute-heart-failure
  6. McMurray JJ, Adamopoulos S, Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33 (14):1787–1847.
  7. Adams KF, Fonarow GC, Emerman CL et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149 (2):209–216.
  8. Hindricks G. IN-TIME: The Influence of Implant-Based Home Monitoring on the Clinical Management of Heart Failure Patients with an Impaired Left Ventricular Function. Congress of Heart Failure Association 2013. Available at: http://www.escardio.org / about / press / press-releases / esc13‑­amsterdam / Pages / hotline-two-in-time.aspx
  9. Abraham WT, Compton S, Haas G, et al. Superior performance of intrathoracic impedance-derived fluid index versus daily weight monitoring in heart failure patients. Results of the Fluid Accumulation Status Trial. Late Breaking Clinical Trials. J Card Fail. November 2009;15 (9):813.
  10. Abraham WT1, Adamson PB, Bourge RC et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet. 2011 Feb 19;377 (9766):658–66.
  11. Fonarow GC, Adams K, Abraham WT. Risk Stratification for In-Hospital Mortality in Heart Failure Using Classification and Regression Tree (CART) Methodology: Analysis of 33,046 Patients in the ADHERE Registry. J Card Fail. 2003;9 (5) Suppl 1: S79.
  12. Gheorghiade M, Gattis WA, O’Connor CM et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worse­ning heart failure: a randomized controlled trial. JAMA. 2004;291 (16):1963–1971.
  13. Forrester JS, Diamond GA, Swan HJ. Correlative classification of clinical and hemodynamic function after acute myocardial infarction. Am J Cardiol. 1977 Feb;39 (2):137–45.
  14. Nohria A1, Mielniczuk LM, Stevenson LW. Evaluation and monitoring of patients with acute heart failure syndromes. Am J Cardiol. 2005 Sep 19;96 (6A): 32G-40G.
  15. Pang PS, Collins SP, Sauser K et al. Assessment of dyspnea early in acute heart failure: patient characteristics and response differen­ces between likert and visual analog scales. Acad Emerg Med. 2014 Jun;21 (6):659–66.
  16. Lucas C, Johnson W, Hamilton MA et al. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J. 2000 Dec;140 (6):840–7.
  17. Мареев Ю. В. Герасимова В. В. Горюнова Т. А. и соав. Факторы определяющие прогноз при хронической сердечной недостаточности: Роль ширины и морфологии комплекса QRS. Журнал Сердечная Недостаточность. 2012;13 (5):255–266.
  18. Sanders-van Wijk S, Maeder MT et al. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF. Circ Heart Fail. 2014 Jan;7 (1):131–9
  19. Bhalla V, Willis S, Maisel AS et al. B-type natriuretic peptide: the level and the drug – partners in the diagnosis of congestive heart failure. Congest Heart Fail. 2004 Jan-Feb;10 (1 Suppl 1):3–27.
  20. Braunstein JB, Anderson GF, Gerstenblith G et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol. 2003 Oct 1;42 (7):1226–33.
  21. Вёрткин А. Л., Петровская Т. П. Острая декомпенсация сердечной недостаточности – старая проблема в свете новых возможностей. Врач скорой помощи. 2014;4:4–9.
  22. Федотов П. А., Ситникова М. Ю., Сафьянова Н. В. и соавторы. Особенности ведения пациента с коморбидной патологией. Лечение ХСН ишемического генеза карведилолом с сопутствующей ХОБЛ. Земский врач. 2012;6:31–37.
  23. Федотов П. А., Ситникова М. Ю., Шапорова Н. Л., Марченко В. Н. Течение хронической обструктивной болезни легких в сочетании с хронической сердечной недостаточностью на фоне лечения с применением небиволола. Пульмонология. 2011;5:53–56.
  24. Мареев В. Ю., Выгодин В. А., Беленков Ю. Н. ДиУретическая терапия Эффективными дозами перораЛьных диуретиков торасемида (диувера) и фуросемида в лечении больных с обострением Хронической Сердечной Недостаточности (ДУЭЛЬ–ХСН). Журнал Сердечная Недостаточность. 2011;12 (3):3–10.
  25. Bart BA, Goldsmith SR, Lee KL et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med. 2012;367 (24):2296–2304.
  26. Chen HH, Anstrom KJ, Givertz MM et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA. 2013 Dec 18;310 (23):2533–43.
  27. Swedberg K, Young JB, Anand IS et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med. 2013 Mar 28;368 (13):1210–9.
  28. Ponikowski P, van Veldhuisen DJ, Comin-Colet J et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2014 Aug 31. Available at: http://dx.doi.org / 10.1093 / eurheartj / ehu385
  29. Javaheri S, Shukla R, Zeigler H, Wexler L. Central sleep apnea, right ventricular dysfunction, and low diastolic blood pressure are predictors of mortality in systolic heart failure. J Am Coll Cardiol. 2007 May 22;49 (20):2028–34.
  30. Khayat R, Abraham W, Patt B et al. Central sleep apnea is a predictor of cardiac readmission in hospitalized patients with systolic heart failure. J Card Fail. 2012 Jul;18 (7):534–40.
  31. Моисеев B. C., Терещенко С. Н., Павликова Е. П. Явелов И. С. Национальные рекомендации по диагностике и лечению острой сердечной недостаточности. Кардиоваскулярная терапия и профилактика. 2006;5 (6 Прил 1):1–30.
  32. Tavazzi L, Senni M, Metra M et al. Multicenter prospective observational study on acute and chronic heart failure: one-year follow-up results of IN-HF (Italian Network on Heart Failure) outcome registry. Circ Heart Fail. 2013 May;6 (3):473–81.
  33. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med. 1987 Jun 4;316 (23):1429–35.
  34. Swedberg K, Kjekshus J, Snapinn S. Long-term survival in severe heart failure in patients treated with enalapril. Ten year follow-up of CONSENSUS I. Eur Heart J. 1999 Jan;20 (2):136–9.
  35. Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med. 1992 Sep 3;327 (10):669–77.
  36. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993 Oct 2;342 (8875):821–8.
  37. Национальные рекомендации по диагностике и лечению больных острым инфарктом миокарда с подъемом сегмента ST ЭКГ. Доступно на: http://www.scardio.ru / recommendations / approved000ED / default.asp
  38. Sigurdsson A, Swedberg K. Left ventricular remodelling, neurohormonal activation and early treatment with enalapril (CONSENSUS II) following myocardial infarction. Eur Heart J. 1994 May;15 (Suppl B): 14–9.
  39. ISIS-4: a randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS‑4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet. 1995 Mar 18;345 (8951):669–85.
  40. Мареев В. Ю., Агеев Ф. Т., Арутюнов Г. П. и др. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Журнал Сердечная Недостаточность. 2013;14 (7): 379–472.
  41. Fonarow GC, Abraham WT, Albert NM et al. Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program. J Am Coll Cardiol. 2008 Jul 15;52 (3):190–9.
  42. Jondeau G, Neuder Y, Eicher JC et al. B-CONVINCED: Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode. Eur Heart J. 2009 Sep;30 (18):2186–92.
  43. Böhm M, Link A, Cai D et al. Beneficial association of β-blocker therapy on recovery from severe acute heart failure treatment: data from the Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support trial. Crit Care Med. 2011 May;39 (5):940–4.
  44. Packer M, Coats AJ, Fowler MB et al. Effect of carvedilol on survi­val in severe chronic heart failure. N Engl J Med. 2001 May 31;344 (22):1651–8.
  45. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999 Sep 2;341 (10):709–17.
  46. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation. 1991 Jun;83 (6):1849–65.
  47. Brown RD, Ambler SK, Mitchell MD, Long CS. The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. Annu Rev Pharmacol Toxicol. 2005;45:657–87.
  48. Azibani F, Devaux Y, Coutance G et al. Aldosterone inhibits the fetal program and increases hypertrophy in the heart of hypertensive mice. PLoS ONE. 2012 May 30;7 (5):e38197.
  49. Weir RA, Tsorlalis IK, Steedman T et al. Aldosterone and cortisol predict medium-term left ventricular remodelling following myocardial infarction. Eur J Heart Fail. 2011 Dec;13 (12):1305–13.
  50. Fraccarollo D, Berger S, Galuppo P et al. Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction. Circulation. 2011 Feb 1;123 (4):400–8.
  51. Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003 Apr 3;348 (14):1309–21.
  52. Pitt B, White H, Nicolau J et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol. 2005 Aug 2;46 (3):425–31.
  53. Pitt B, Gheorghiade M, Zannad F et al. Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction less-than or equal to 30 %. Eur J Heart Fail. 2006 May;8 (3):295–301.
  54. Montalescot G, Zannad F, Lopez de Sa E et al. Early administration of eplerenone in patients with acute myocardial infarction without heart failure: results of the randomized, double-blind, placebo-controlled REMINDER Trial. American College of Cardiology 2013 Scientific Sessions. 2013 Mar 10.
  55. Mentz RJ, Cotter G, Cleland JG et al. International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short-term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial. Eur J Heart Fail. 2014 Jun;16 (6):614–24.
  56. Jorge E, Baptista R, Martins H et al. Digoxin in advanced heart failure patients: a question of rhythm. Rev Port Cardiol. 2013 Apr;32 (4):303–10.
  57. Mareev Y, Danilyn M, Mareev V, Belenkov V. Different influence of digoxin on prognosis in CHF according the heart rhythm. Eur J Heart Fail. 2014;16 (s2):267.
  58. Беленков Ю. Н., Атьков О. Ю., Цибекмахер Т. Д. Влияние быстрой дигитализации на функцию левого желудочка по данным эхокардиографии. Кардиология. 1977;17 (9):46–50.
  59. Freeman JV, Yang J, Sung SH et al. Effectiveness and safety of digo­xin among contemporary adults with incident systolic heart failure. Circ Cardiovasc Qual Outcomes. 2013 Sep 1;6 (5):525–33.
  60. Garg R, Gorlin R, Smith T, Yusuf S. The effect of digoxin on morta­lity and morbidity in patients with heart failure. N Engl J Med. 1997 feb 20;336 (8):525–33.
  61. Rathore SS, Curtis JP, Wang Y et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003 Feb 19;289 (7):871–8.
  62. Gheorghiade M. Effect of digoxin in high-risk chronic heart failure patients: a prespecified subgroup analysis of the Digitalis Investigation Group trial. Heart Failure Congress 2012; May 21, 2012, Belgrade, Serbia.
  63. Uretsky BF, Young JB, Shahidi FE et al. Randomized study assessing the effect of digoxin withdrawal in patients with mild to mode­rate chronic congestive heart failure: results of the PROVED trial. J Am Coll Cardiol. 1993 Oct; 22 (4):955–62.
  64. Packer M, Gheorghiade M, Young JB et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. N Engl J Med. 1993 Jul 1;329 (1):1–7.
  65. Swedberg K, Komajda M, Böhm M et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010 Sep 11;376 (9744):875–85.
  66. Borer JS, Böhm M, Ford I et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. Eur Heart J. 2012 Nov;33 (22):2813–20.
  67. Sargento L, Satendra M, Longo S et al. Heart rate reduction with ivabradine in patients with acute decompensated systolic heart failure. Am J Cardiovasc Drugs. 2014 Jun;14 (3):229–35.
Mareev V. Yu., Arutyunov G. P., Astashkin E. I. et al. Acute decompensated heart failure. Consensus of Russian experts, 2014. Russian Heart Failure Journal. 2014;15 (5): 321–336

To access this material please log in or register

Register Authorize
Ru En